trastuzumab
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
trastuzumab
May 16, 2024, 14:15 |
Insight
Elie G. Dib: Excited to share the results of the TAPUR study
Elie G. Dib, Associate Director of the Haematology-Oncology Training Program at Saint Joseph Mercy Hospital,…
May 15, 2024, 13:45 |
Blog
Sergio Cifuentes Canaval: Exciting insights from the MRI-guided optimization study in HER2+ breast cancer!
Sergio Cifuentes Canaval, Student Fellow at National Autonomous University of Mexico, shared a post on LinkedIn:…
May 11, 2024, 11:23 |
Insight
Matt Sagan: Moving from HER2+ to HER2-low to HER2- ultralow
Matt Sagan, Co-Founder and CEO of FiBioMed, shared a post by Paolo Tarantino on X,…
Apr 15, 2024, 14:38 |
Insight
New Paper Alert! Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response
Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response Authors: Carmine Valenza,…
Apr 8, 2024, 14:26 |
Drugs
Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH
Dana-Farber’s Breast Oncology Center posted on X: "We are leading a randomized Phase 2 trial for…
Mar 27, 2024, 13:02 |
Blog
Erman Akkus: ESMO-2023, hepatobiliary and pancreatic cancers
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "ESMO-2023, hepatobiliary and pancreatic…
Mar 22, 2024, 16:49 |
Insight
Guilherme Nader Marta: CLEOPATRA trial analysis shows that complete response at first imaging re-evaluation correlates with longer PFS and OS
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on LinkedIn: “Many patients with…
Mar 22, 2024, 06:12 |
Drugs
Paolo Tarantino: We’re running SATEEN, the first trial of sacituzumab govitecan + trastuzumab in patients with HER2 + MBC
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post by Marta…
Feb 8, 2024, 17:54 |
Insight
Paolo Tarantino: Few treatments in oncology allow to achieve more than 50% intracranial response rates, with durable efficacy
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared ESMO Open's post on X/Twitter, adding: "One…
Dec 10, 2023, 17:32 |
Blog
Wafik S. El-Deiry: I wore my chemistry tie today in honor of your visit to Providence and Brown University
Wafik S. El-Deiry, the Director of the Legorreta Cancer Center of Brown University, posted on LinkedIn:…
1
2
All:
12
Posts:
1 - 10
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Barbara Jereczek-Fossa has been elected as the ESTRO President-elect!
Facebook
RSS Feed
Twitter
Linkedin
Youtube